Evaluation of Dosimetric Parameters and Disease Response After 125Iodine Transperineal Brachytherapy for Low- and Intermediate-Risk Prostate Cancer

摘要: Purpose To analyze dosimetric outcomes after permanent brachytherapy for men with low-risk and "low-tier" intermediate-risk prostate cancer explore the relationship between traditional values, V100 (volume of receiving 100% prescribed dose) D90 (minimum dose to 90% prostate), risk biochemical failure. Methods Materials A total 1,006 consecutive patients underwent implantation July 20, 1998, Oct 23, 2003. Most (58%) had disease; remaining 42% comprised a selected low-tier subgroup patients. The minimum peripheral (MPD) was 144 Gy. All implants used 0.33 mCi 125 I sources using preplan technique featuring right-left symmetry strong posterior-peripheral bias. Sixty-five percent 6 months androgen deprivation therapy. Postimplantation dosimetry calculated day-28 CT scans. Results With median follow-up 54 months, actuarial 5-year rate freedom from recurrence (bNED) 95.6% ± 1.6%. Median 105% MPD, 92%, V150 58%, V200 9%. Dosimetric values were not predictive on univariate or multivariate analysis. Analysis by number showed statistically significant increases in all time (D90, V100, V150, V200; p Conclusions In contrast some previous studies, did correlate first treated at British Columbia Cancer Agency. Despite only our bNED rates are indistinguishable series that reported higher values.